Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 1.00 |
| ▸ | PGK1 | P00558 | 5/20 | 0.81 |
| ▸ | PGK2 | P07205 | 5/20 | 0.81 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.76 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.59 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260549 | 0.82 | PTPN1 (0.68) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL5499124 | 0.79 | PGK1 (0.71) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL778974 | 0.79 | PTPN1 (0.65) | PTPN1PGK1PGK2PTPN5 | |
| SCHEMBL6838700 | 0.79 | PGK1 (0.78) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL14076365 | 0.79 | PGK1 (0.78) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL5499239 | 0.79 | PGK1 (0.78) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL6155317 | 0.79 | PGK1 (0.78) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL2637465 | 0.79 | PGK1 (0.78) | PTPN1PGK1PGK2PTPN5PTPN2 | |
| SCHEMBL9648116 | 0.77 | PTPN1 (0.62) | PTPN1PGK1PGK2PTPN5 | |
| SCHEMBL1766233 | 0.77 | PTPN1 (0.62) | PTPN1PGK1PGK2PTPN5PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10985446-B1 | Physically reconfigurable structurally embedded vascular antenna and method of making | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2021-04-20 | — | — | US | claimed |
| US-10944178-B1 | Physically reconfigurable structurally embedded vascular antenna | GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE | 2021-03-09 | — | — | US | claimed |
| US-10129975-B1 | Liquid metal interfaces for flexible and reconfigurable electronics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2018-11-13 | — | — | US | claimed |
| US-20250334727-A1 | OPTICAL FILTER, OPTICAL DEVICE, AND LIGHT-ABSORBING COMPOSITION | NIPPON SHEET GLASS CO LTD (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20250231329-A1 | LIGHT-ABSORBING COMPOSITION, LIGHT-ABSORBING FILM, AND OPTICAL FILTER | NIPPON SHEET GLASS CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-12313869-B2 | Optical filter, optical device, and light-absorbing composition | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2025-05-27 | — | — | US | disclosed |
| US-12287501-B2 | Light-absorbing composition, light-absorbing film, and optical filter | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2025-04-29 | — | — | US | disclosed |
| US-12071542-B2 | Light-absorbing composition and optical filter | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2024-08-27 | — | — | US | disclosed |
| US-20240192414-A1 | LAMINATE, VISUAL-LINE TRACKING SYSTEM, AND HEAD-MOUNTED DISPLAY | FUJIFILM CORPORATION (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20230400615-A1 | OPTICAL FILTER, OPTICAL DEVICE, AND LIGHT-ABSORBING COMPOSITION | NIPPON SHEET GLASS COMPANY, LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| WO-2023282261-A1 | LAMINATE, SIGHT LINE TRACKING SYSTEM, AND HEAD-MOUNTED DISPLAY | 富士フイルム株式会社 | 2023-01-12 | — | — | WO | disclosed |
| WO-2018132846-A1 | MATERIALS AMD METHODS FOR BUFFERING ACTIVE CHLORINE SOLUTIONS | PHARMOCON LLC (US) | 2018-07-19 | — | — | WO | disclosed |
| US-9939727-B2 | Method for manufacturing patterned object, patterned object, and light irradiation apparatus | USHIO DENKI KABUSHIKI KAISHA (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20180052952-A9 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180052952-A9 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-20170052447-A1 | METHOD FOR MANUFACTURING PATTERNED OBJECT, PATTERNED OBJECT, AND LIGHT IRRADIATION APPARATUS | USHIO DENKI KABUSHIKI KAISHA (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20140222398-A1 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140222398-A1 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2001027077-A2 | HYDROXYSULFONYLALKYLENE-, PHOSPHONOALKYLENE- OR DIFLUORO(PHOSPHONONON)METHYL- SUBSTITUTED BENZENE, OR BENZOFURAN DERIVATIVES AS NON-PEPTIDIC CDC25 INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | NR3C2, REN, AGTR1 | PTPN1 1928/4885PGK1 1713/4885PGK2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.